Mar 27, 2023
Publications
Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy
Publication: bioRxiv
Authors: Christian Garde, Michail A Pavlidis, Pablo Garces, Emma J Lange, Sri H Ramarathinam, Mateo Sokac, Kirti Pandey, Pouya Faridi, Johanne Ahrenfeldt, Shanzou Chung, Stine Friis, Daniela Kleine-Kohlbrecher, Nicolai J Birkbak, Jens V Kringelum, Birgitte Rono, Anthony W Purcell, Thomas Trolle
Mar 26, 2023
Press releases
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy
This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy
Mar 15, 2023
Press releases
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.
Dec 15, 2022
Press releases
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
Evaxion today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023.
Subscribe to our Newsletter
Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.